Birelentinib

Birelentinib
INN: birelentinib
Clinical data
Other names	BTK-IN-30; DZD-8586; GTPL13735
Identifiers
	IUPAC name [(2S,5S)-5-[4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl]oxan-2-yl]methanol;
CAS Number	2662512-15-2;
PubChem CID	156565109;
ChemSpider	129957181;
UNII	Z2F599L9GD;
KEGG	D13253;
Chemical and physical data
Formula	C23H21F2N5O3
Molar mass	453.450 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](OC[C@@H]1C2=NC(=C3N2N=CN=C3N)C4=CC=C(C=C4)OC5=C(C(=CC=C5)F)F)CO;
	InChI InChI=InChI=1S/C23H21F2N5O3/c24-17-2-1-3-18(19(17)25)33-15-7-4-13(5-8-15)20-21-22(26)27-12-28-30(21)23(29-20)14-6-9-16(10-31)32-11-14/h1-5,7-8,12,14,16,31H,6,9-11H2,(H2,26,27,28)/t14-,16+/m1/s1; Key:NQJKXHPWHYRGST-ZBFHGGJFSA-N;

Birelentinib is an investigational new drug that is being developed by for the treatment of immune thrombocytopenia (ITP), and chronic lymphocytic leukemia. It is a dual Bruton's tyrosine kinase (BTK) and tyrosine-protein kinase Lyn inhibitor.^[1]^[2]

References

↑ "Birelentinib". AdisInsight. Dizal Pharmaceutical. Retrieved 3 July 2026.
↑ Zhou K, Wang T, Yang W, Mi JQ, Gao S, Zhu H, Guo X, Ding K, Xiang Y, Cai H, Cui G, Zhuang Y, Jing H, Su L, Huang R (2025-11-03). "Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report". Blood. 146 (Supplement 1): 3889. doi:10.1182/blood-2025-3889. ISSN 0006-4971.